5 Mosaic Laboratories Ltd 15234739 false 2024-05-01 2025-10-31 2025-10-31 The principal activity of the company is Other engineering activities Digita Accounts Production Advanced 6.30.9574.0 true 15234739 2024-05-01 2025-10-31 15234739 2025-10-31 15234739 bus:Director1 1 2025-10-31 15234739 bus:Director1 2 2025-10-31 15234739 bus:Director2 2025-10-31 15234739 bus:Director2 1 2025-10-31 15234739 bus:Director2 2 2025-10-31 15234739 bus:Director3 2025-10-31 15234739 bus:Director3 1 2025-10-31 15234739 bus:Director3 2 2025-10-31 15234739 bus:Director4 2025-10-31 15234739 bus:Director4 1 2025-10-31 15234739 bus:Director4 2 2025-10-31 15234739 bus:OrdinaryShareClass1 bus:CumulativeShares 2025-10-31 15234739 core:CurrentFinancialInstruments 2025-10-31 15234739 core:CurrentFinancialInstruments core:WithinOneYear 2025-10-31 15234739 core:BetweenTwoFiveYears 2025-10-31 15234739 core:WithinOneYear 2025-10-31 15234739 core:FurnitureFittingsToolsEquipment 2025-10-31 15234739 core:LandBuildings 2025-10-31 15234739 core:MotorVehicles 2025-10-31 15234739 core:OtherPropertyPlantEquipment 2025-10-31 15234739 bus:SmallEntities 2024-05-01 2025-10-31 15234739 bus:AuditExemptWithAccountantsReport 2024-05-01 2025-10-31 15234739 bus:FullAccounts 2024-05-01 2025-10-31 15234739 bus:SmallCompaniesRegimeForAccounts 2024-05-01 2025-10-31 15234739 bus:RegisteredOffice 2024-05-01 2025-10-31 15234739 bus:Director1 2024-05-01 2025-10-31 15234739 bus:Director1 1 2024-05-01 2025-10-31 15234739 bus:Director1 2 2024-05-01 2025-10-31 15234739 bus:Director2 2024-05-01 2025-10-31 15234739 bus:Director2 1 2024-05-01 2025-10-31 15234739 bus:Director2 2 2024-05-01 2025-10-31 15234739 bus:Director3 2024-05-01 2025-10-31 15234739 bus:Director3 1 2024-05-01 2025-10-31 15234739 bus:Director3 2 2024-05-01 2025-10-31 15234739 bus:Director4 2024-05-01 2025-10-31 15234739 bus:Director4 1 2024-05-01 2025-10-31 15234739 bus:Director4 2 2024-05-01 2025-10-31 15234739 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-05-01 2025-10-31 15234739 bus:PrivateLimitedCompanyLtd 2024-05-01 2025-10-31 15234739 bus:Agent1 2024-05-01 2025-10-31 15234739 core:FurnitureFittingsToolsEquipment 2024-05-01 2025-10-31 15234739 core:LandBuildings 2024-05-01 2025-10-31 15234739 core:MotorVehicles 2024-05-01 2025-10-31 15234739 core:OfficeEquipment 2024-05-01 2025-10-31 15234739 core:OtherPropertyPlantEquipment 2024-05-01 2025-10-31 15234739 core:PlantMachinery 2024-05-01 2025-10-31 15234739 1 2024-05-01 2025-10-31 15234739 countries:EnglandWales 2024-05-01 2025-10-31 15234739 bus:Director1 1 2024-04-30 15234739 bus:Director1 2 2024-04-30 15234739 bus:Director2 1 2024-04-30 15234739 bus:Director2 2 2024-04-30 15234739 bus:Director3 1 2024-04-30 15234739 bus:Director3 2 2024-04-30 15234739 bus:Director4 1 2024-04-30 15234739 bus:Director4 2 2024-04-30 15234739 2023-10-25 2024-04-30 15234739 2024-04-30 15234739 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-04-30 15234739 core:CurrentFinancialInstruments 2024-04-30 15234739 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 15234739 core:BetweenTwoFiveYears 2024-04-30 15234739 core:WithinOneYear 2024-04-30 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 15234739

Mosaic Laboratories Ltd

Annual Report and Unaudited Financial Statements

for the Period from 1 May 2024 to 31 October 2025

 

Mosaic Laboratories Ltd

Contents

Company Information

1

Directors' Report

2

Balance Sheet

3

Notes to the Unaudited Financial Statements

4 to 11

 

Mosaic Laboratories Ltd

Company Information

Directors

Graeme Kirkpatrick

Edgar Whately

Jordan Luke Rathbone

David Arthur Brick

Registered office

167-169 Great Portland Street,
5th Floor,
London
W1W 5PF

Accountants

Mortimer Childe Accounting Ltd 53 High Street
Cleobury Mortimer
Worcestershire
DY14 8DQ

 

Mosaic Laboratories Ltd

Directors' Report for the Period from 1 May 2024 to 31 October 2025

The directors present their report and the financial statements for the period from 1 May 2024 to 31 October 2025.

Directors of the company

The directors who held office during the period were as follows:

Graeme Kirkpatrick

Edgar Whately (appointed 19 June 2024)

Jordan Luke Rathbone (appointed 13 August 2024)

David Arthur Brick (appointed 19 June 2024)

Principal activity

The principal activity of the company is Other engineering activities

Small companies provision statement

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the Board on 27 July 2026 and signed on its behalf by:
 

.........................................
Graeme Kirkpatrick
Director

 

Mosaic Laboratories Ltd

(Registration number: 15234739)
Balance Sheet as at 31 October 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

5

2,531,210

-

Current assets

 

Debtors

6

106,206

683

Cash at bank and in hand

 

293,029

3,317

 

399,235

4,000

Creditors: Amounts falling due within one year

7

(441,323)

(4,760)

Net current liabilities

 

(42,088)

(760)

Total assets less current liabilities

 

2,489,122

(760)

Provisions for liabilities

(514,082)

-

Net assets/(liabilities)

 

1,975,040

(760)

Capital and reserves

 

Called up share capital

8

1,204

100

Retained earnings

1,973,836

(860)

Shareholders' funds/(deficit)

 

1,975,040

(760)

For the financial period ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the Board on 27 July 2026 and signed on its behalf by:
 

.........................................
Graeme Kirkpatrick
Director

 

Mosaic Laboratories Ltd

Notes to the Unaudited Financial Statements for the Period from 1 May 2024 to 31 October 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
167-169 Great Portland Street,
5th Floor,
London
W1W 5PF

The principal place of business is:
Ditton Priors Trading Estate
Station Road
Bridgnorth
Shropshire
WV16 6SS

These financial statements were authorised for issue by the Board on 27 July 2026.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Disclosure of long or short period

A longer period of accounts were prepared to cover initial set up costs for the business in the first year of trading. Comparatives are not comparable as there was no trading in the previous period.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Mosaic Laboratories Ltd

Notes to the Unaudited Financial Statements for the Period from 1 May 2024 to 31 October 2025

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and Machinery

15% Reducing balance

Office Equipment

20% Straight line

Motor Vehicles

25% Reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

Mosaic Laboratories Ltd

Notes to the Unaudited Financial Statements for the Period from 1 May 2024 to 31 October 2025

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 5 (2024 - 1).

 

Mosaic Laboratories Ltd

Notes to the Unaudited Financial Statements for the Period from 1 May 2024 to 31 October 2025

4

Profit/loss before tax

Arrived at after charging/(crediting)

2025
£

2024
£

Depreciation expense

396,307

-

 

Mosaic Laboratories Ltd

Notes to the Unaudited Financial Statements for the Period from 1 May 2024 to 31 October 2025

5

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
 £

Motor vehicles
 £

Other tangible assets
£

Total
£

Cost or valuation

Additions

421,712

22,311

182,066

2,301,428

2,927,517

At 31 October 2025

421,712

22,311

182,066

2,301,428

2,927,517

Depreciation

Charge for the period

-

5,577

45,516

345,214

396,307

At 31 October 2025

-

5,577

45,516

345,214

396,307

Carrying amount

At 31 October 2025

421,712

16,734

136,550

1,956,214

2,531,210

 

Mosaic Laboratories Ltd

Notes to the Unaudited Financial Statements for the Period from 1 May 2024 to 31 October 2025

6

Debtors

Current

2025
£

2024
£

Trade debtors

17,258

-

Prepayments

33,272

569

Other debtors

55,676

114

 

106,206

683

7

Creditors

Creditors: amounts falling due within one year

Note

2025
£

2024
£

Due within one year

 

Loans and borrowings

9

-

3,900

Trade creditors

 

84,145

-

Taxation and social security

 

192,647

-

Accruals and deferred income

 

163,518

860

Other creditors

 

1,013

-

 

441,323

4,760

8

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary shares of £1 each

1,104

1,104

100

100

       

9

Loans and borrowings

Current loans and borrowings

2025
£

2024
£

Other borrowings

-

3,900

 

Mosaic Laboratories Ltd

Notes to the Unaudited Financial Statements for the Period from 1 May 2024 to 31 October 2025

10

Obligations under leases and hire purchase contracts

Operating leases

The total of future minimum lease payments is as follows:

2025
£

2024
£

Not later than one year

35,000

-

Later than one year and not later than five years

60,751

-

95,751

-

The amount of non-cancellable operating lease payments recognised as an expense during the period was £9,249 (2024 - £Nil).

 

Mosaic Laboratories Ltd

Notes to the Unaudited Financial Statements for the Period from 1 May 2024 to 31 October 2025

11

Related party transactions

Transactions with directors

2025

At 1 May 2024
£

Advances to director
£

Repayments by director
£

At 31 October 2025
£

Graeme Kirkpatrick

Interest free advances were made during the period

-

5,301

-

5,301

-

-

-

-

-

5,301

-

5,301

Edgar Whately

Interest free advances were made during the period

-

5,301

-

5,301

-

-

-

-

-

5,301

-

5,301

David Arthur Brick

Interet free advances were made during the period

-

5,301

-

5,301

-

-

-

-

-

5,301

-

5,301

Jordan Luke Rathbone

Interest free advances were made during the period

-

5,301

-

5,301

-

-

-

-

-

5,301

-

5,301